EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real‐Life Application of a Point‐of‐Care Biosensor for Phenylalanine in Patients With Phenylketonuria

Corentin Gondrand, Anna T Reischl-Hajiabadi iD, Estelle Bonedeau, Nicolas Weiß, Gerd Schneider, Maurice Fahn, Frederic Myers, Philipp Minel Städle, Kathrin Jeltsch, Georg F Hoffmann, Jürgen G Okun, Dorothea Haas und 3 weitere

Journal of Inherited Metabolic Disease · 2026

DOI: 10.1002/jimd.70187 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Inherited Metabolic Disease, 2026. Verfasst von Corentin Gondrand und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology, Max Planck Institute for Medical Research, Heidelberg, Germany. Hauptthemen laut MEDLINE: Biosensing Techniques, Phenylalanine, Phenylketonurias, Point-of-Care Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fraunhofer-Max Planck Cooperation Program, Marie Skłodowska-Curie grant agreement (H2020-MSCAITN-CONSENSE), M. Lomtadze.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phenylketonuria (PKU) is a rare metabolic disorder causing elevated phenylalanine (PHE) levels requiring lifelong dietary or pharmacological management and regular monitoring. Current PHE monitoring methods, such as tandem mass spectrometry (FIA‐MS/MS), are laboratory and sample transport‐dependent, leading to delays in obtaining results. This highlights the need for accessible point‐of‐care (PoC) solutions. Building on a previously developed bioluminescence‐based PHE quantification method, we created a PoC PHE sensor integrated with a smartphone app ( phenyx app) for real‐time monitoring and data sharing. In a clinical study with PKU patients, we evaluated the reliability of the sensor and the app by comparing at‐home PHE measurements with dried blood samples (DBS) analyzed using the gold standard FIA‐MS/MS. We also assessed time differences between sampling and results, sensor practicality, and user experience. Forty‐seven PKU patients (median age 10.0 years, range 0.7–53.4) performed one supervised and four at‐home measurements using the PHE sensor, alongside DBS sampling for FIA‐MS/MS. The sensor showed higher PHE values than FIA‐MS/MS, with a mean difference of 84.8 μmol/L ( p = 0.0017). Variability was influenced by test supervision (clinic vs. home) and test kit age (greater difference in older batches, p = 0.001). Usability of the PHE sensor and phenyx app was rated favorably; all patients preferred the PHE sensor over laboratory testing. PoC measurement using the PHE sensor and phenyx app is feasible, reliable, and provides rapid results comparable to FIA‐MS/MS, representing a key step toward patient self‐testing. Trial Registration: NCT05998109, NCT06940193, DRKS00031972.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosensing TechniquesPhenylalaninePhenylketonuriasPoint-of-Care SystemsAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedYoung AdultDried Blood Spot TestingRapid Diagnostic TestsReproducibility of ResultsSmartphoneTandem Mass Spectrometry

Stichwörter der Autor:innen

PKUPhenylketonuriaat‐home testbiosensorphenylalanine hydroxylase deficiencypoint‐of‐care testing

Substanzen

Phenylalanine

Autor:innen und Institutionen

  • Department of Chemical Biology, Max Planck Institute for Medical Research, Heidelberg, Germany.
  • Medical Faculty of Heidelberg, Department of Pediatrics, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Heidelberg, Germany.
  • Phellow Seven GmbH, Heidelberg, Germany.
  • Frederic Myers Consulting (JERY), Reutlingen, Germany.
  • École Polytechnique Fédérale de Lausanne, Institute of Chemical Sciences and Engineering, NCCR in Chemical Biology, Lausanne, Switzerland.

ORCID-Profile: Anna T Reischl-Hajiabadi, Sven F Garbade, Thomas Opladen

Förderung

  • Fraunhofer-Max Planck Cooperation Program
  • Marie Skłodowska-Curie grant agreement (H2020-MSCAITN-CONSENSE)
  • M. Lomtadze

Zitieren

APA

Gondrand, C., Reischl-Hajiabadi, A. T., Bonedeau, E., Weiß, N., Schneider, G., Fahn, M., Myers, F., Städle, P. M., Jeltsch, K., Hoffmann, G. F., Okun, J. G., Haas, D., Garbade, S. F., Johnsson, K., & Opladen, T. (2026). Real‐Life Application of a Point‐of‐Care Biosensor for Phenylalanine in Patients With Phenylketonuria. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70187

Vancouver

Gondrand C, Reischl-Hajiabadi AT, Bonedeau E, Weiß N, Schneider G, Fahn M, et al. Real‐Life Application of a Point‐of‐Care Biosensor for Phenylalanine in Patients With Phenylketonuria. Journal of Inherited Metabolic Disease. 2026. doi:10.1002/jimd.70187

BibTeX
@article{Gondrand2026,
  author = {Gondrand, Corentin and Reischl-Hajiabadi, Anna T and Bonedeau, Estelle and Weiß, Nicolas and Schneider, Gerd and Fahn, Maurice and Myers, Frederic and Städle, Philipp Minel and Jeltsch, Kathrin and Hoffmann, Georg F and Okun, Jürgen G and Haas, Dorothea and Garbade, Sven F and Johnsson, Kai and Opladen, Thomas},
  title = {Real‐Life Application of a Point‐of‐Care Biosensor for Phenylalanine in Patients With Phenylketonuria},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  doi = {10.1002/jimd.70187}
}
Kostenlos starten →